Ann: Appendix 4D and Half Yearly Financial Report, page-164

Sorry Ice I can’t agree with you on this . Traders cause a lot of grief for Biotecs that are not cash flow positive on the ASX that’s why Qbiotics won’t float untill their product is in the market and making money . Qbiotics don’t even have a product to market yet and the company is valued at over 200 million . They have no problems if they do a CR and the last one raised 30 million and was oversubscribed . Unfortunately companies on the ASX who are not cash flow positive like AHZ get their SP hammered if they miss targets or run low on cash . Once this happens it makes it almost impossible to do a CR . Believe me Ice ,I have two friends who do nothing but trade Biotecs and even I do to a degree . I have made quite a bit with GSS over the last year without diminishing my stake in the company . At this stage it’s way to late for AHZ to do a CR and it won’t be supported . Looking at the announcement this morning it seems management are prepared to take shares instead of salaries which reinforces why thoughts that a deal is on the cards